PTK2 and neoplasm: Encouragingly, similar studies in PDAC showed that FAK inhibition synergises with Abraxane to reduce cell proliferation in vitro and decrease tumour growth in vivo [59], further highlighting the potential of FAK dual-targeting with standard-of-care chemotherapy.